EMBC
Embecta Corp.
$3.19
-0.18
(-5.34%)
Mkt Cap
189.26M
Volume
1,362,410
52W Range
2.77-15.55
Sector
Healthcare
Beta
0.81
EPS (TTM)
1.91
P/E Ratio
1.67
Revenue (TTM)
1.04B
Rev Growth (5Y)
-0.1%
EPS Growth (5Y)
-26.2%
Company Description
Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.08B | 1.12B | 1.12B | 1.13B | 1.17B | 1.09B | 1.11B |
| Net Income | 95.40M | 78.30M | 70.40M | 223.60M | 414.80M | 427.60M | 432.00M |
| EPS | 1.64 | 1.36 | 1.23 | 3.92 | 7.31 | 7.50 | 7.58 |
| Free Cash Flow | 182.40M | 19.90M | 41.20M | 388.20M | 417.00M | 456.60M | 436.00M |
| FCF / Share | 3.13 | 0.34 | 0.72 | 6.80 | 7.34 | 8.01 | 7.65 |
| Operating CF | 191.70M | 35.70M | 67.70M | 412.20M | 456.00M | 498.50M | 505.00M |
| Total Assets | 1.09B | 1.29B | 1.21B | 1.09B | 788.00M | 738.00M | 745.00M |
| Total Debt | 1.43B | 1.61B | 1.64B | 1.64B | 4.10M | 5.00M | 0 |
| Cash & Equiv | 225.50M | 267.50M | 326.30M | 330.90M | 0 | 0 | 0 |
| Book Value | (651.20M) | (738.30M) | (821.70M) | (891.40M) | 594.00M | 572.00M | 577.00M |
| Return on Equity | N/A | N/A | N/A | N/A | 0.70 | 0.75 | 0.75 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 221.80M | 261.20M | 264.00M | 295.50M | 259.00M | 261.90M | 286.10M | 272.50M | 287.20M | 277.30M | 281.90M | 286.10M |
| Net Income | (4.10M) | 44.10M | 26.40M | 45.50M | 23.50M | (700,000) | 14.60M | 14.70M | 28.90M | 20.10M | 6.00M | 15.20M |
| EPS | -0.07 | 0.75 | 0.45 | 0.78 | 0.40 | -0.01 | 0.25 | 0.25 | 0.50 | 0.35 | 0.10 | 0.27 |
| Free Cash Flow | 30.60M | 16.60M | 76.70M | 80.80M | 31.70M | (6.80M) | 26.60M | (11.80M) | 20.90M | (15.80M) | 20.40M | (16.10M) |
| FCF / Share | 0.52 | 0.28 | 1.31 | 1.38 | 0.55 | -0.12 | 0.45 | -0.20 | 0.36 | -0.27 | 0.36 | -0.28 |
| Operating CF | 31.10M | 17.20M | 84.00M | 81.20M | 31.80M | (5.30M) | 26.60M | (2.10M) | 24.30M | (13.10M) | 29.60M | (9.30M) |
| Total Assets | 1.03B | 1.06B | 1.09B | 1.16B | 1.12B | 1.15B | 1.29B | 1.27B | 1.20B | 1.22B | 1.21B | 1.25B |
| Total Debt | 1.36B | 1.39B | 1.43B | 1.50B | 1.55B | 1.58B | 1.61B | 1.65B | 1.66B | 1.64B | 1.64B | 1.64B |
| Cash & Equiv | 184.90M | 201.30M | 225.50M | 230.60M | 209.30M | 210.00M | 267.50M | 275.10M | 299.80M | 298.70M | 326.30M | 317.40M |
| Book Value | (626.10M) | (613.10M) | (651.20M) | (669.60M) | (736.20M) | (768.80M) | (738.30M) | (763.70M) | (769.60M) | (793.50M) | (821.70M) | (809.40M) |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
EMBC News
EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Embecta Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EMBC
Embecta Corp. (EMBC) Faces Securities Class Action for Allegedly Concealing Competitive Threats to Pen Needle Business -- HBSS
EMBECTA CORP. CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Embecta Corp. and Encourages Investors to Contact the Firm
EMBECTA CORP. CLASS ACTION ALERT: Bragar Eagel & Squire, P.C.
Embecta Corp. (EMBC) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Bronstein, Gewirtz & Grossman LLC Urges Embecta Corp. Investors to Act: Class Action Filed Alleging Investor Harm
EMBC DEADLINE: Levi & Korsinsky Reminds Embecta Corp. Investors of Upcoming Securities Class Action Deadline
EMBC Investment Loss: Embecta Investors that Lost Money after Insulin Pen Issues Disclosed are Notified to Contact BFA Law about the Filed Securities Fraud Class Action
Embecta Corp. (EMBC) Faces Securities Class Action Over Alleged Concealed Material Risks to Pen Needle Revenue- HBSS